作者
Xiuxing Wang, Kailin Yang, Qiulian Wu, Leo JY Kim, Andrew R Morton, Ryan C Gimple, Briana C Prager, Yu Shi, Wenchao Zhou, Shruti Bhargava, Zhe Zhu, Li Jiang, Weiwei Tao, Zhixin Qiu, Linjie Zhao, Guoxing Zhang, Xiqing Li, Sameer Agnihotri, Paul S Mischel, Stephen C Mack, Shideng Bao, Jeremy N Rich
发表日期
2019/8/7
期刊
Science translational medicine
卷号
11
期号
504
页码范围
eaau4972
出版商
American Association for the Advancement of Science
简介
Glioblastoma stem cells (GSCs) reprogram glucose metabolism by hijacking high-affinity glucose uptake to survive in a nutritionally dynamic microenvironment. Here, we trace metabolic aberrations in GSCs to link core genetic mutations in glioblastoma to dependency on de novo pyrimidine synthesis. Targeting the pyrimidine synthetic rate-limiting step enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase (CAD) or the critical downstream enzyme dihydroorotate dehydrogenase (DHODH) inhibited GSC survival, self-renewal, and in vivo tumor initiation through the depletion of the pyrimidine nucleotide supply in rodent models. Mutations in EGFR or PTEN generated distinct CAD phosphorylation patterns to activate carbon influx through pyrimidine synthesis. Simultaneous abrogation of tumor-specific driver mutations and DHODH activity with clinically approved inhibitors …
引用总数
学术搜索中的文章